Limits...
Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.

Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT - BMC Cancer (2009)

Bottom Line: But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far.The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells.ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.

View Article: PubMed Central - HTML - PubMed

Affiliation: Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan, PR China. luzejun.01@163.com

ABSTRACT

Background: Antibody-based immunotherapy has achieved some success for cancer. But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far. It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy.

Methods: The membrane proteins of lung adenocarcinoma cell line A549 were used to immunize the BALB/c mice. A monoclonal antibody 4E7 (McAb4E7) was produced with hybridoma technique. MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549 cells. Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies based on 2-DE and mass spectrometry were employed to detect and identify the corresponding antigen of McAb4E7.

Results: The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells. By the proteomic technologies, we identified that ATP synthase beta subunit (ATPB) was the corresponding antigen of McAb4E7. Then, flow cytometric analysis demonstrated the localization of the targeting antigen of McAb4E7 was on the A549 cells surface. Furthermore, immunohistochemistry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively.

Conclusion: In the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen. ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.

Show MeSH

Related in: MedlinePlus

2-DE/Western blot analysis of the targeting antigen of McAb4E7. (A) The quarter 2-DE map of A549 cells, black arrow indicated the targeting antigen (B) Western blot detection for the targeting protein spot recognized by McAb4E7.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2654462&req=5

Figure 4: 2-DE/Western blot analysis of the targeting antigen of McAb4E7. (A) The quarter 2-DE map of A549 cells, black arrow indicated the targeting antigen (B) Western blot detection for the targeting protein spot recognized by McAb4E7.

Mentions: To recognize the targeting antigen of McAb4E7, 2-DE/Western blot was performed with A549 cells. Preliminary experiment with Immobiline Dry-Strips (7 cm, 3–10 NL) indicated that the positive protein spot was located at PI 5 and MW 55 kDa in the gel. To improve the resolution, 17 cm gels (17 cm, 3–10 NL) were used, and a quarter of the gel was subjected to Western blot in view of the PI and MW of the corresponding antigen of McAb4E7 (Figure 4). Then, the protein spot, corresponding to those showing a positive reaction with the antibody 4E7 in 2-DE/Western blot, was excised from the gel (Figure 4A).


Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.

Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT - BMC Cancer (2009)

2-DE/Western blot analysis of the targeting antigen of McAb4E7. (A) The quarter 2-DE map of A549 cells, black arrow indicated the targeting antigen (B) Western blot detection for the targeting protein spot recognized by McAb4E7.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2654462&req=5

Figure 4: 2-DE/Western blot analysis of the targeting antigen of McAb4E7. (A) The quarter 2-DE map of A549 cells, black arrow indicated the targeting antigen (B) Western blot detection for the targeting protein spot recognized by McAb4E7.
Mentions: To recognize the targeting antigen of McAb4E7, 2-DE/Western blot was performed with A549 cells. Preliminary experiment with Immobiline Dry-Strips (7 cm, 3–10 NL) indicated that the positive protein spot was located at PI 5 and MW 55 kDa in the gel. To improve the resolution, 17 cm gels (17 cm, 3–10 NL) were used, and a quarter of the gel was subjected to Western blot in view of the PI and MW of the corresponding antigen of McAb4E7 (Figure 4). Then, the protein spot, corresponding to those showing a positive reaction with the antibody 4E7 in 2-DE/Western blot, was excised from the gel (Figure 4A).

Bottom Line: But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far.The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells.ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.

View Article: PubMed Central - HTML - PubMed

Affiliation: Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan, PR China. luzejun.01@163.com

ABSTRACT

Background: Antibody-based immunotherapy has achieved some success for cancer. But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far. It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy.

Methods: The membrane proteins of lung adenocarcinoma cell line A549 were used to immunize the BALB/c mice. A monoclonal antibody 4E7 (McAb4E7) was produced with hybridoma technique. MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549 cells. Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies based on 2-DE and mass spectrometry were employed to detect and identify the corresponding antigen of McAb4E7.

Results: The monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells. By the proteomic technologies, we identified that ATP synthase beta subunit (ATPB) was the corresponding antigen of McAb4E7. Then, flow cytometric analysis demonstrated the localization of the targeting antigen of McAb4E7 was on the A549 cells surface. Furthermore, immunohistochemistry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively.

Conclusion: In the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen. ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.

Show MeSH
Related in: MedlinePlus